NASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis $4.64 +0.05 (+1.09%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.40▼$4.7550-Day Range$2.51▼$4.6652-Week Range$2.47▼$9.24Volume348,257 shsAverage Volume300,679 shsMarket Capitalization$174.37 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vigil Neuroscience alerts: Email Address Vigil Neuroscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside244.8% Upside$16.00 Price TargetShort InterestHealthy7.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.10) to ($2.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.06 out of 5 starsMedical Sector394th out of 936 stocksBiological Products, Except Diagnostic Industry56th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingVigil Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVigil Neuroscience has only been the subject of 2 research reports in the past 90 days.Read more about Vigil Neuroscience's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.14% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently decreased by 48.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIGL. Previous Next 2.5 News and Social Media Coverage News SentimentVigil Neuroscience has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Vigil Neuroscience this week, compared to 2 articles on an average week.Search Interest11 people have searched for VIGL on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vigil Neuroscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders33.03% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vigil Neuroscience's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.10) to ($2.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vigil Neuroscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Vigil Neuroscience Stock (NASDAQ:VIGL)Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Read More VIGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIGL Stock News HeadlinesJuly 26 at 10:45 AM | markets.businessinsider.comBuy Rating Affirmed on Vigil Neuroscience’s VG-3927 Based on Positive Phase 1 Results and Strong Industry OutlookJuly 25 at 9:18 PM | markets.businessinsider.comBuy Rating Affirmed for Vigil Neuroscience Inc. on Promising VG-3927 Phase 1 Study Results and Alzheimer’s Treatment Market PotentialJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! July 25 at 10:55 AM | uk.finance.yahoo.comCoinDesk 20 Performance Update: XRP and NEAR Help Push Index UpwardJuly 25 at 10:55 AM | markets.businessinsider.comPromising Early Results for Vigil Neuroscience’s VG-3927 Support Strong Buy RatingJuly 25 at 10:55 AM | benzinga.comSmall Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease BimarkerJuly 25 at 8:28 AM | americanbankingnews.comVigil Neuroscience (NASDAQ:VIGL) Given "Buy" Rating at HC WainwrightJuly 24 at 7:00 AM | globenewswire.comVigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's DiseaseJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 20, 2024 | americanbankingnews.comVigil Neuroscience (NASDAQ:VIGL) Given New $17.00 Price Target at HC WainwrightJuly 19, 2024 | markets.businessinsider.comVigil Neuroscience Inc: Promising Drug Development and Potential for Accelerated FDA Approval Drive Buy RatingJuly 18, 2024 | globenewswire.comVigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International ConferenceJuly 18, 2024 | globenewswire.comVigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSPJuly 8, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)July 8, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)June 27, 2024 | investorplace.comWhy Is Vigil Neuroscience (VIGL) Stock Up 32% Today?June 27, 2024 | globenewswire.comVigil Neuroscience Announces $40 Million Strategic Investment from SanofiJune 26, 2024 | businesswire.comAugustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological DiseasesSee More Headlines Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIGL CUSIPN/A CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$23.00 Low Stock Price Target$4.00 Potential Upside/Downside+244.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.96% Return on Assets-55.14% Debt Debt-to-Equity RatioN/A Current Ratio12.38 Quick Ratio12.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book1.43Miscellaneous Outstanding Shares37,580,000Free Float25,170,000Market Cap$174.37 million OptionableNot Optionable Beta2.00 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Ivana Magovcevic-Liebisch J.D. (Age 57)Ph.D., President, CEO & Director Comp: $908.25kSharon MoraniSenior Director of Facilities & OperationsDr. David Gray Ph.D. (Age 49)Chief Scientific Officer Ms. Leah GibsonVice President of Investor Relations and Corporate CommunicationsMr. Christopher Verni J.D. (Age 49)General Counsel & Corporate Secretary April Effort M.B.A.M.S., VP & Head of Corporate DevelopmentMr. Evan A. Thackaberry DABT (Age 51)Ph.D., Senior VP & Head of Early Development Christian Mirescu Ph.D.VP & Head of NeuroimmunologyWeeteck Yeo Ph.D.Senior Vice President of Strategic OperationsAndreas Meier M.D.Senior Vice President of Clinical & Medical SciencesMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSVectivBioNASDAQ:VECTAnavex Life SciencesNASDAQ:AVXLProKidneyNASDAQ:PROKValnevaNASDAQ:VALNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 95,276 shares on 5/10/2024Ownership: 2.380%Ivana Magovcevic-LiebischBought 4,000 shares on 11/20/2023Total: $15,000.00 ($3.75/share)View All Insider TransactionsView All Institutional Transactions VIGL Stock Analysis - Frequently Asked Questions How have VIGL shares performed this year? Vigil Neuroscience's stock was trading at $3.38 at the beginning of 2024. Since then, VIGL shares have increased by 37.3% and is now trading at $4.64. View the best growth stocks for 2024 here. How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) posted its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.10. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIGL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.